OncoMed Pharma (OMED) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds 29,000 jobs in September
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
OncoMed Pharmaceuticals (OMED) PT Lowered to $15 at Jefferies
May 6, 2016 8:03 AM EDTJefferies analyst Brian Abrahams kept a Buy rating but lowered his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $15.00 (from $16.00) following Q1 results.
Abrahams commented, "OMED's financials and clinical trial progress were mostly in line for the quarter, and while more key data... More
